ArticleJournal of clinical laboratory analysis2020
A potential disease monitoring and prognostic biomarker in cervical cancer patients: The clinical application of circular RNA_0018289.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic and diagnostic value of circRNA expression in cervical cancer: a meta analysis.Frontiers in oncology · 2024Pooled it
- What is the role of circRNAs in the pathogenesis of cervical cancer? A systematic literature review.Frontiers in genetics · 2024Pooled it
- Pooled it
- Circular RNAs modulate cancer drug resistance: advances and challenges.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Exploring the impact of circRNAs on cancer glycolysis: Insights into tumor progression and therapeutic strategies.Non-coding RNA research · 2024Review
- Circular RNA in cervical cancer: Fundamental mechanism and clinical potential.Non-coding RNA research · 2024Review
- Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.Cell communication and signaling : CCS · 2024Review
- Exosome-delivered circRNA circSYT15 contributes to cisplatin resistance in cervical cancer cells through the miR-503-5p/RSF1 axis.Cell cycle (Georgetown, Tex.) · 2023Article
- CircRNA hsa_circ_0001627 aggravates cervical cancer progression through upregulation of FNDC3B and activating PI3K/mTOR signaling pathway.Journal of cell communication and signaling · 2023Article
- CircRNA hsa_circ_0018289 exerts an oncogenic role in cervical cancer progression through miR-1294/ICMT axis.Journal of clinical laboratory analysis · 2022Article
- Identification of a novel circ_0018289/miR-183-5p/TMED5 regulatory network in cervical cancer development.World journal of surgical oncology · 2021Article
- Hsa_circ_0000520 overexpression increases CDK2 expression via miR-1296 to facilitate cervical cancer cell proliferation.Journal of translational medicine · 2021Article
- Investigating the Underlying Mechanisms of Circular RNAs and Their Application in Clinical Research of Cervical Cancer.Frontiers in genetics · 2021Review
- A Comprehensive Overview of circRNAs: Emerging Biomarkers and Potential Therapeutics in Gynecological Cancers.Frontiers in cell and developmental biology · 2021Review
- Circular RNAs: Novel biomarkers for cervical, ovarian and endometrial cancer (Review).Oncology reports · 2020Review
- A potential disease monitoring and prognostic biomarker in cervical cancer patients: The clinical application of circular RNA_0018289.Journal of clinical laboratory analysis · 2020Article
- Circular RNAs: Emerging Role in Cancer Diagnostics and Therapeutics.Frontiers in molecular biosciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the tumor circular RNA_0018289 (circ_0018289) expression and its correlation with clinical characteristics as well as survival profiles in cervical cancer patients.
methodsA hundred and ninety-two cervical cancer patients who received surgical resection were recruited in this prospective study. Tumor tissue and paired adjacent tissue were obtained during the surgery, in which circ_0018289 expression was detected by reverse transcription quantitative polymerase chain reaction. Disease-free survival (DFS) and overall survival (OS) were recorded.
resultsCirc_0018289 expression was upregulated in tumor tissue compared with paired adjacent tissue (P < .001), and receiver operative characteristic curve disclosed its good value for separating tumor tissue from adjacent tissue with an area under curve of 0.907 (95% CI: 0.879-0.935). Additionally, tumor circ_0018289 expression was positively associated with tumor size (P = .009), lymph node metastasis (P = .005) and Federation International of Gynecology and Obstetrics stage (P = .005). The DFS (P = .005) and OS (P = .015) were both worse in patients with circ_0018289 high expression compared to patients with circ_0018289 low expression. Meanwhile, in patients with circ_0018289 high expression, DFS and OS were the longest in patients with high+ expression followed by patients with high++ expression, and the shortest in patients with high+++ expression. Moreover, circ_0018289 high expression could independently predict worse DFS in the total cervical cancer patients (P = .042).
conclusionCirc_0018289 could serve as a potential disease monitoring and prognostic biomarker in cervical cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.